Metastatic HR+/HER2− Breast Cancer Market Report 2026

Metastatic HR+/HER2− Breast Cancer Market Overview

• Metastatic HR+/HER2− Breast Cancer market size has reached to $10.89 billion in 2025 • Expected to grow to $17.26 billion in 2030 at a compound annual growth rate (CAGR) of 9.6% • Growth Driver: Increasing Demand For Hormone Replacement Therapy (HRT) Propel The Market Growth • Market Trend: Advancements In Combination Therapy Boosting Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Metastatic HR+/HER2− Breast Cancer Market?

Metastatic HR+/HER2− breast cancer refers to a form of breast cancer where the cancer cells have spread beyond the breast to other parts of the body. Metastatic HR+/HER2− breast cancer is treated using targeted therapies, hormonal treatments, and chemotherapy to manage disease progression and improve patient outcomes. The main types of drugs in metastatic HR+/HER2− breast cancer are paclitaxel, tamoxifen, vinblastine, raloxifene, docetaxel, and other drugs. Paclitaxel is a chemotherapy drug that inhibits cancer cell growth by stabilizing microtubules, preventing cell division. These are used for treatment, including radiation therapy, vitamin therapy, macrobiotic diets, homeopathy, and herbal medication, and are used by various end users, such as hospitals, clinics, and other end users.

What Is The Metastatic HR+/HER2− Breast Cancer Market Growth Forecast?

The metastatic hr+/her2− breast cancer market size is expected to see strong growth in the next few years. It will grow to $17.26 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to growth in targeted therapies like cdk4/6 inhibitors, expanding immunotherapy research, increasing use of genomic profiling, rising demand for combination regimens, enhanced patient monitoring technologies. Major trends in the forecast period include precision hormonal therapy advancements, AI-enhanced treatment personalization, data-driven monitoring of treatment response, virtual simulation for oncology training, automated diagnostic workflow integration.

What Is The Driver Of The Metastatic HR+/HER2− Breast Cancer Market?

The increasing hormone replacement therapy (HRT) is expected to propel the growth of the metastatic HR+/HER2− breast cancer market going forward. Hormone replacement therapy (HRT) is a medical treatment used to supplement or replace hormones that are at lower levels in the body, most commonly during menopause or in cases of hormone deficiencies. The increasing hormone replacement therapy (HRT) is due to their effectiveness in improving treatment outcomes, reduced side effects compared to traditional therapies, and advancements in precision medicine. Hormonal replacement therapy (HRT) can support metastatic HR+/HER2− breast cancer by alleviating the symptoms of estrogen deficiency associated with menopause, such as hot flashes and vaginal dryness, without interfering with the effectiveness of endocrine therapies, as it primarily targets hormone imbalances rather than the cancerous cells, ensuring better quality of life for patients undergoing cancer treatment. For instance, in October 2023, according to the Health Professional Academy, a UK-based personalized health professional learning platform, in 2022/23, close to 11 million hormone replacement therapy (HRT) prescriptions were issued, marking an almost 50% rise from the previous year. Therefore, the increasing hormone replacement therapy (HRT) drives the metastatic HR+/HER2− breast cancer industry.

Key Players In The Global Metastatic HR+/HER2− Breast Cancer Market

Major companies operating in the metastatic hr+/her2− breast cancer market are Pfizer Inc., F Hoffmann‑La Roche AG, AstraZeneca PLC, Eli Lilly and Company, Merck & Co, Arvinas Inc, Olema Pharmaceuticals Inc, Genentech Inc, Veru Pharma, DualityBio Inc, BioNTech SE, Evgen Pharma, EQRx Inc, G1 Therapeutics Inc, Immutep Ltd, RemeGen Co Ltd, SynCore Biotechnology Co Ltd, Allarity Therapeutics AS, Jiangsu Alphamab Biopharmaceuticals Co Ltd, Byondis BV, Jiangsu Hansoh Pharmaceutical Co Ltd, Shanghai Miracogen Inc, Eisai Co Ltd, Tyme Inc, Orion Pharma

Global Metastatic HR+/HER2− Breast Cancer Market Trends and Insights

Major companies operating in the metastatic HR+/HER2− breast cancer market are developing combination therapy to expand their indications, market reach, and treatment options. Combination therapy is a treatment approach that involves the simultaneous use of two or more therapeutic agents, which may include chemotherapy, targeted therapy, immunotherapy, hormone therapy, or other modalities, to treat a medical condition more effectively by targeting different pathways, enhancing the overall treatment response, and reducing the likelihood of the condition, such as cancer, developing resistance to any single treatment. For instance, in July 2023, Merck & Co., Inc., a US-based pharmaceutical company, announced the Phase 3 KEYNOTE-756 trial evaluating KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, in combination with chemotherapy approved by the Food and Drug Administration, a US-based government agency. The trial met its primary endpoint by significantly improving the pathological complete response (pCR) rate in patients with high-risk, early-stage ER+/HER2- breast cancer. KEYNOTE-756 is the first positive Phase 3 trial demonstrating a statistically significant improvement in pCR rate with an immunotherapy regimen in the neoadjuvant setting for the patient population. The trial assessed KEYTRUDA with chemotherapy as a neoadjuvant treatment, followed by adjuvant KEYTRUDA plus endocrine therapy for high-risk, early-stage ER+/HER2- breast cancer.

What Are Latest Mergers And Acquisitions In The Metastatic HR+/HER2− Breast Cancer Market?

In November 2023, Carrum Health, a US-based company that offers healthcare solutions, partnered with Texas Oncology to provide breast cancer treatment. Through this collaboration, Carrum Health aims to offer patients a bundled package for breast cancer care, including two years of coverage for chemotherapy, radiation, and symptom management from Texas Oncology, with the goal of providing high-quality, cost-effective care. Texas Oncology is a US-based company that offers treatment for metastatic HR+/HER2− breast cancer.

What Defines the Metastatic HR+/HER2− Breast Cancer Market?

The metastatic HR+/HER2− breast cancer market consists revenues earned by entities by providing services such as endocrine therapy, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic HR+/HER2− breast cancer market also includes sales of CDK4/6 inhibitors, PI3K inhibitors, mTOR inhibitors, and chemotherapy agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Metastatic HR+/HER2- Breast Cancer Market Report 2026?

The metastatic hr+/her2- breast cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic hr+/her2- breast cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.